Ranbaxy US Arm Acquires US Firm Production Unit

New Delhi, July 23: | Updated: Jul 25 2002, 05:30am hrs
Ranbaxy Laboratories’ wholly owned US subsidiary, Ranbaxy Pharmaceuticals Inc, has acquired the liquid manufacturing facility of New York-based Signature Pharmaceuticals Inc on an asset purchase basis.

The fully automated manufacturing and packaging line facility with state-of-the-art testing and quality assurance capabilities will be the first liquid manufacturing unit of Ranbaxy in the US. The acquisition will also bring in advanced capabilities for research, development, manufacturing and distribution of controlled substances.

This acquisition will be a strategic fit for its business in the US for manufacturing certain liquid based dosage forms that would enable in-house production and strengthen its liquid product pipeline. This will result in cost savings with respect to the currently outsourced products and also exhibit validation services for Ranbaxy’s products in the US.

Ohm Laboratories, acquired by Ranbaxy in September 1995, provides advanced manufacturing capabilities and processes to create quality OTC, branded and generic products. It offers a comprehensive development scale up and manufacturing of a diversified line of over-the-counter and Rx generic pharmaceuticals. Ranbaxy Laboratories’ president (pharmaceuticals) Dr Brian Tempest said, “Signature’s acquisition provides strategic platform to Ranbaxy’s US operations vis-a-vis liquid dosage forms.